Person

Back to overview

Khanna Nina

Gender Female
Institute Abteilung für Allgemeine Innere Medizin Medizinische Universitätsklinik A Universitätsspital Basel
ORCID 0000-0002-2642-419X
Show all

Projects as responsible applicant

Responsible applicant Institution of higher education Start End date Funding scheme

T-cell immunity to Aspergillus fumigatus in patients after hematopoietic stem cell transplantation
Khanna Nina Institution abroad - IACH 01.10.2008 31.03.2010 Fellowships for prospective researchers

Epstein-Barr Virus-specific T Memory Stem Cell Therapy to Treat EBV-driven Lymphomas/Diseases
Khanna Nina University of Basel - BS 01.02.2022 31.01.2026 Project funding (Div. I-III)

Relevance of different CD4+ T-cell subsets for antifungal defense. What is aberrant in immunocompromised patients?
Khanna Nina University of Basel - BS 01.01.2013 31.12.2015 Ambizione

Relevance of different CD4+ T-cell subsets for antifungal defense. What is aberrant in immunocompromised patients?
Khanna Nina University of Basel - BS 01.01.2016 31.12.2016 Ambizione

Projects as co-applicant

Responsible applicant Institution of higher education Start End date Funding scheme

New anti-bacterial coatings for implant materials
Fromm Katharina M. University of Fribourg - FR 01.10.2011 31.03.2014 Project funding (Div. I-III)

NCCR AntiResist (phase I)
Dehio Christoph University of Basel - BS 01.08.2020 31.07.2024 National Centres of Competence in Research (NCCRs)

Projects as member of staff

Responsible applicant Institution of higher education Start End date Funding scheme

Relevance of different CD4+ T-cell subsets for antifungal defense. What is aberrant in immunocompromised patients?
Khanna Nina University of Basel - BS 01.01.2013 31.12.2015 Ambizione

Relevance of different CD4+ T-cell subsets for antifungal defense. What is aberrant in immunocompromised patients?
Khanna Nina University of Basel - BS 01.01.2016 31.12.2016 Ambizione

Projects as project partner

Responsible applicant Institution of higher education Start End date Funding scheme

Using Genetic Risk Factors to Stratify Antifungal Prophylaxis in Patients with Acute Myeloid Leukemia
Bochud Pierre-Yves University of Lausanne - LA 01.06.2018 30.11.2022 Investigator Initiated Clinical Trials (IICT)

-